Lipid nanoparticles for topical and transdermal application for alopecia treatment: Development, physicochemical characterization, and in vitro release and penetration studies

International Journal of Nanomedicine

Volumn 9, Issue 1, 2014, Pages 1231-1242

  Gomes, Maria João ^a   Martins, Susana ^b,c   Ferreira, Domingos ^b   Segundo, Marcela A ^a   Reis, Salette ^a  

^a Department of Chemical Sciences   (Denmark)

^b UNIVERSITY OF PORTO   (Portugal)

^c UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Alopecia; Anti alopecia therapy; Fnasteride; Minoxidil; Nanostructured lipid carriers (NLC)

Indexed keywords

FINASTERIDE; LIPID NANOPARTICLE; MINOXIDIL; NANOPARTICLE; UNCLASSIFIED DRUG; DELAYED RELEASE FORMULATION; DERMATOLOGICAL AGENT; LIPID;

ALOPECIA; ANIMAL TISSUE; ARTICLE; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; CRYSTALLIZATION; DERMIS; DRUG FORMULATION; DRUG PENETRATION; DRUG STABILITY; DRUG STORAGE; HAIR FOLLICLE; IN VITRO STUDY; NONHUMAN; PARTICLE SIZE; PHASE TRANSITION; PHYSICAL CHEMISTRY; SKIN; SWINE; ZETA POTENTIAL; ANIMAL; CHEMISTRY; DELAYED RELEASE FORMULATION; DRUG DELIVERY SYSTEM; HUMAN; MALE; METABOLISM; NANOMEDICINE; NANOTECHNOLOGY; PIG; SURFACE PROPERTY; TOPICAL DRUG ADMINISTRATION; ULTRASTRUCTURE;

ADMINISTRATION, TOPICAL; ALOPECIA; ANIMALS; DELAYED-ACTION PREPARATIONS; DERMATOLOGIC AGENTS; DRUG DELIVERY SYSTEMS; DRUG STABILITY; FINASTERIDE; HUMANS; LIPIDS; MALE; MINOXIDIL; NANOMEDICINE; NANOPARTICLES; NANOTECHNOLOGY; PARTICLE SIZE; SKIN; SURFACE PROPERTIES; SWINE;

EID: 84897766091     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S45561     Document Type: Article

References (24)

1. Padois K, Cantiéni C, Bertholle V, Bardel C, Pirot F, Falson F. Solid lipid nanoparticles suspension versus commercial solutions for dermal delivery of minoxidil. Int J Pharm. 2011;416:300-304.
2. Ellis JA, Sinclair RD. Male pattern baldness: current treatments, future prospects. Drug Discov Today. 2008;13:791-797.
3. Wosicka H, Cal K. Targeting to the hair follicles: current status and potential. J Dermatol Sci. 2010;57:83-89.
4. Alzolibani AA. Epidemiologic and genetic characteristics of alopecia areata (part 1). Acta Dermatovenerol Alp Panonica Adriat. 2011;20(4):191-198.
5. Coda AB, Sinha AA. Integration of genome-wide transcriptional and genetic profles provides insights into disease development and clinical heterogeneity in alopecia areata. Genomics. 2011;98(6):431-439.
6. Desai P, Patlolla RR, Singh M. Interaction of nanoparticles and cell-penetrating peptides with skin for transdermal drug delivery. Mol Membr Biol. 2010;27(7):247-259.
7. Chourasia R, Jain SK. Drug targeting through pilosebaceous route. Curr Drug Targets. 2009;10(10):950-967.
8. Pardeike J, Hommoss A, Müller RH. Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products. Int J Pharm. 2009;366(1-2):170-184.
9. Torchilin VP, editor. Nanoparticulates as Drug Carriers. London: Imperial College Press; 2006; Chapter 9.
10. Schäfer-Korting M, editor. Drug Delivery. Berlin: Springer-Verlag; 2010;115-143.
11. Kwon TK, Kim JC. In vitro skin permeation of monoolein nanoparticles containing hydroxypropyl beta-cyclodextrin/minoxidil complex. Int J Pharm. 2010;392(1-2):268-273.
12. Souto EB, Müller RH. Cosmetic features and applications of lipid nanoparticles (SLN, NLC). Int J Cosmet Sci. 2008;30(3):157-165.
13. Tabbakhian M, Tavakoli N, Jaafari MR, Daneshamouz S. Enhancement of follicular delivery of fnasteride by liposomes and niosomes 1. In vitro permeation and in vivo deposition studies using hamster flank and ear models. Int J Pharm. 2006;323(1-2):1-10.
14. Ricci M, Puglia C, Bonina F, Giovanni CD, Giovagnoli S, Rossi C. Evaluation of indomethacin percutaneous absorption from nanostructured lipid carriers (NLC): in vitro and in vivo studies. J Pharm Sci. 2005;94(5):1149-1159.
15. Goldman MP, Bacci PA, Leibaschoff G, Hexsel D, Angelini F. Cellulite: Pathophysiology and Treatment. New York: Taylor and Francis Group; 2006.
16. Al-Bader T, Davis M, Laloeuf A, Rawlings AV, Inventors; Oriflame Cosmetics SA, assignee. Topical cosmetic compositions for treating or preventing cellulite. Patent EP2009/054043. April 3, 2009.
17. Mohanraj V, Chen Y. Nanoparticles a review. Tropical Journal of Pharmaceutical Research. 2006;5(1):561-573.
18. Mehnert W, Mäder K. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev. 2001;47(2-3):165-196.
19. Schäfer-Korting M, Mehnert W, Korting HC. Lipid nanoparticles for improved topical application of drugs for skin diseases. Adv Drug Deliv Rev. 2007;59:427-443.
20. Das S, Chaudhury A. Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery. AAPS PharmSciTech. 2011;12:62-76.
21. Saupe A, Wissing SA, Lenk A, Schmidt C Müller RH. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) structural investigations on two different carrier systems. Biomed Mater Eng. 2005;15(5):393-402.
22. Bunjes H, Koch MH, Westesen K. Influence of emulsifers on the crystallization of solid lipid nanoparticles. J Pharm Sci. 2003;92(7): 1509-1520.
23. Zimmermann E, Souto EB, Müller RH. Physicochemical investigations on the structure of drug-free and drug-loaded solid lipid nanoparticles (SLN) by means of DSC and 1HNMR. Pharmazie. 2005;60(7): 508-513.
24. Mukherjee S, Ray S, Thakur RS. Solid lipid nanoparticles: a modern formulation approach in drug delivery system. Indian J Pharm Sci. 2009;71:349-358.